Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label Atalante X. Show all posts
Showing posts with label Atalante X. Show all posts

Friday, June 14, 2024

EarlyExo: Effects of Atalante X exoskeleton on gait recovery in non- or poorly ambulatory patients with hemiparesis in the acute/subacute phase

This had better get you 100% walking recovery in the hospital, it'll never be able to be used outside the clinic.

Functional Ambulation Categories (FAC) is a 6-point functional walking test. I guess I'm a 5.

Scoring and Score Interpretation[2]:

 

 EarlyExo: Effects of Atalante X exoskeleton on gait recovery in non- or poorly ambulatory patients with hemiparesis in the acute/subacute phase

M. Steinböck 1 , A. Buetikofer 1 , L. M. Huber 1 , K. Jahn 1,2 , F. Müller 1 1 Schoen Clinic Bad Aibling, Department of Neurology, Research Group, Bad Aibling, Germany 2 German Center for Vertigo and Balance Disorders (DSGZ), Ludwig-Maximilians University of Munich, Germany 
 
Background: 
 
According to recent studies approximately 30 % of stroke survivors experience significant disability lasting beyond one month following their stroke [1]. This prolonged disability not only contributes to extended hospital stays but also poses challenges in returning home and resuming work activities, thereby incurring substantial financial burdens [2]. --is acknowledged to enhance overall recovery [3, 4]. Numerous robotic aids designed for physiotherapeutic neurological rehabilitation are available on the mar- ket, one of them being motorized exoskeletons. These devices comprise orthoses attached to limbs, offering motorized assistance during walking. The Atalante X exoskeleton (Wandercraft, France) allows individuals with significant walking impairments to stand and walk without hands support. Its functionalities extend to facilitating strength and balance exercises. Previous research has shown that robotic-supported gait therapy effectively assists post-stroke patients in regaining their ability to walk [5, 6, 7]. The interventional, international and multicentre study EarlyExo is a prospective randomized controlled trial (RCT), which investigates the therapeutic efficacy of Atalante X gait therapy. Its focus lies on non- or poorly ambulatory stroke patients experiencing hemiparesis during the acute/subacute phase, particularly within one to four months post-stroke. 
 
Methods: 
 
In the acute/subacute phase following a stroke, patients with hemiparesis and a Functional Ambulation Category (FAC) value below 2 are eligible for participation. The FAC is a 6-point scale assessing walking ability based on required physical support or supervision. Below FAC 2 identifies individuals in need of continuous manual assistance for mobility. Patients are enrolled across five European centers located in Spain, France, and Germany. After providing written informed consent, patients are randomly assigned to either the control or intervention group, both of which undergo a six-week, intensive therapy regimen. The intervention group, which uses the Atalante X exoskeleton, engages in three weekly sessions, complemented by two conventional physiotherapy sessions. Each session lasts one hour. The control group receives five one-hour sessions of conventional physiotherapy per week, with no access to electromechanical devices dedicated to gait training during the study. At baseline, throughout the intervention period, at discharge and six months post-stroke, a blinded evaluator assesses the patients. Additionally, therapists are surveyed regarding the workload experienced during therapy sessions and patients are requested to provide self-assessments of their health-related quality of life. 
 
Hypothesis and Objectives: 
 
It is hypothesized that a higher proportion of patients will attain a FAC score of ≥ 4 upon completion of the intervention phase, indicating their ability to walk independently on level ground. The overall aim of this study is to test whether early and intensive walking therapy using the Atalante X exoskeleton leads to a superior recovery of functional walking compared to the control group, specifically in hemiparetic patients with limited or poor ambulatory capacities. Secondarily, various walking parameters, clinical evalu- ations of leg muscle strength, the subjective experiences of patients, and therapists reported outcomes, are recorded. 
 
Outlook: 
 
In the current recruitment phase, four patients have been enrolled in the German neurological rehabilitation centre Schoen Clinic Bad Aibling. We aim to gather a total sample size of 66 participants across the designated sites, emphasizing a meticulous recruitment process for a representative stroke population.

Tuesday, September 26, 2023

World’s first self-stabilising walking exoskeleton enters stroke rehab trial

Doesn't your competent hospital already have the best of these walking assistants? 

Ask your doctor how this compares to all the other walking assist devices out there.


World’s first self-stabilising walking exoskeleton enters stroke rehab trial

Atalante X is designed to support people with mobility issues


World’s first self-stabilising walking exoskeleton enters stroke rehab trial

The world’s first self-stabilising walking exoskeleton, Atlante X,  has entered a rehabilitation trial in Germany.

The exoskeleton will be provided to patients with hemiparesis, an after-effect of stroke that causes muscle weakness on one side of the body. Atalante X’s efficacy will be compared with standard rehabilitation methods.

The trial, named EarlyExo, will take place at two renowned neurorehabilitation clinics: the Vivantes Klinikum Spandau in Berlin and Schön Klinik Bad Aibling Harthausen near Munich. Both clinics will this month begin recruiting a total of 66 patients.

“Recovery from a stroke and other acute neurological conditions is complex and can take patients, treating therapists, physicians, and carers significant time, effort, and resources,” Professor Jörg Wissel, a neurologist at Vivantes Klinikum Spandau, said in a statement.

The <3 of EU tech

The latest rumblings from the EU tech scene, a story from our wise ol' founder Boris, and some questionable AI art. It's free, every week, in your inbox. Sign up now!

“We look forward to evaluating the potential impact that Atalante X can add in helping patients recover walking ability, trunk stability, balance, weight transfer, and limb function.”

A patient in the Atalante X exoskeleton high-fiving a physical therapist
Atalante X enables multitasking via various exercises from an upright position. Credit: Wandercraft

Atalante X was developed by Wandercraft, a healthtech firm based in Paris. Founded in 2012, the company wants to build a better solution for people deprived of walking than a wheelchair. Its opening proposal, Atalante, was launched in 2019. Wandercraft believes it was the first bipedal walking robot to become a full commercial product.

Atalante X is the second iteration of the tool. Using a proprietary self-balancing feature, the exoskeleton provides hands-free and multi-directional locomotion. Therapists can use the device to personalise task-orientated treatments for each patient’s needs.

Regulators have shown growing faith in the system. In January, the US Food and Drug Administration (FDA) cleared Atalante for use in stroke rehabilitation. Investors have also provided strong support, ploughing a total of around $67mn (€63mn) into Wandercraft.

The trial in Germany provides another opportunity to develop the product.

“This launch in one of Europe’s largest markets reinforces the position of Wandercraft as a global leader in the field of self-stabilizing, assisted locomotion,” said Matthieu Masselin, CEO of Wandercraft.

“It helps provide us with the opportunity to extend the reach of our assistive technology to greater patient populations for treatment and rehabilitation.”

The German launch expands Wandercraft’s strong commercial presence in Europe, which also includes footholds in France and Spain.  The company is now targeting the biggest market of them all: the USA.